tbuckley/cabot-search huggingface dataset:
TCT-82 Evaluation of Current Practices in Transcatheter Aortic Valve Replacement: The WRITTEN (WoRldwIde TAVR ExperieNce) Survey
Authors: Luis Nombela-Franco, Enrico Cerrato, Tamim Nazif, Helene Eltchaninoff, Lars Sondergaard, Henrique Ribeiro, Marco Barbanti, Fabian Nietlispach, Pierfrancesco Agostoni, Ramiro Trillo, Pilar Jimenez, Fabrizio D'Ascenzo, Olaf Wendler, Gabriel Maluenda, Mao Chen, Corrado Tamburino, Carlos Macaya, Martin Leon, Josep Rodés-Cabau
Journal: Journal of the American College of Cardiology (2016)
Targeted deep sequencing reveals clinically relevant subclonal IgHV rearrangements in chronic lymphocytic leukemia
Authors: B Stamatopoulos, A Timbs, D Bruce, T Smith, R Clifford, P Robbe, A Burns, D V Vavoulis, L Lopez, P Antoniou, J Mason, H Dreau, A Schuh
Journal: Leukemia (2016)
A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials
Authors: G Montalban-Bravo, X Huang, E Jabbour, G Borthakur, C D DiNardo, N Pemmaraju, J Cortes, S Verstovsek, T Kadia, N Daver, W Wierda, Y Alvarado, M Konopleva, F Ravandi, Z Estrov, N Jain, A Alfonso, M Brandt, T Sneed, H-C Chen, H Yang, C Bueso-Ramos, S Pierce, E Estey, Z Bohannan, H M Kantarjian, G Garcia-Manero
Journal: Leukemia (2016)
Image Gallery: Multiple pigmented follicular cysts, with a familial association
Authors: E. Varas-Meis, M.-A. González-Morán, M.-A. Rodríquez-Prieto
Journal: British Journal of Dermatology (2016)

Funding sources: none. Conflicts of interest: none declared. Dear Editor, A 45‐year‐old man, with an unremarkable dermatological or family history, presented with asymptomatic bluish‐brown cysts on the forehead and both cheeks since adolescence (a).1,2 The patient had a single 21‐year‐old son with similar facial lesions (b). Anatomical pathology testing revealed stratified epithelial cystic lesions with epidermal keratinization. The content was composed of sheets of keratin and pigmented terminal hair shafts with numerous melanin granules (c). In polariscopy, corticomedullary differentiation was noted (d). We proceeded to remove the cysts with a lancet after a superficial incision with a CO2 laser in superpulsed mode. After 10 months of follow‐up, no recurrences were noted (e). We present the first two cases of multiple pigmented follicular cysts with a familial association.
TCT-117 Impact of Intra-aortic Balloon Pump use on mortality in patients with cardiogenic shock treated with Primary Percutaneous Coronary Intervention: An Observational Study of 21,210 patients with ST-Elevation Myocardial Infarction from the London Heart Attack Group
Authors: Krishnaraj Rathod, Anthony Mathur, Andrew Wragg, Costas O'Mahony, Daniel Jones
Journal: Journal of the American College of Cardiology (2016)
Long-term Outcomes of the Western Australian Trial of Screening for Abdominal Aortic Aneurysms
Authors: Kieran A. McCaul, Michael Lawrence-Brown, James A. Dickinson, Paul E. Norman
Journal: JAMA Internal Medicine (2016)

Mortality from ruptured abdominal aortic aneurysms (AAAs) remains high. The benefit of screening older men for AAAs needs to be assessed in a range of health care settings.To assess the influence of screening for AAAs in men aged 64 to 83 years on mortality from AAAs.This randomized clinical trial performed from April 1, 1996, through March 31, 1999, with a mean of 12.8 years of follow-up (range, 11.6-14.2 years) included a population-based sample from a single metropolitan region in Western Australia identified via the electoral roll. Data analysis was performed from June 1, 2015, to June 1, 2016.Randomization to an invitation to undergo ultrasonography of the abdominal aorta or a control group without invitation.Surgery for and mortality from AAA.A total of 49 801 men aged 64 to 83 years were identified for the study. Men living too far from screening centers (n = 8671) or who died before invitation (n = 2650) were excluded, resulting in 19 249 men in the invited group and 19 231 controls (mean [SD] age, 72.5 [4.6] years; 95% white). Of 19 249 men invited for screening, 12 203 (63.4%) attended. There were more elective operations (536 vs 414, P < .001) and fewer ruptured AAAs (72 vs 99, P = .04) in the invited group compared with the control group. Overall, there were 90 deaths from AAAs in the invited group (mortality rate, 47.86 per 100 000 person-years; 95% CI, 38.93-58.84) and 98 in the control group (52.53 per 100 000 person-years; 95% CI, 43.09-64.03) for a rate ratio of 0.91 (95% CI, 0.68-1.21). For men aged 65 to 74 years, the AAA mortality rate in the invited group was 34.52 per 100 000 person-years (95% CI, 26.02-45.81) compared with 37.67 per 100 000 person-years (95% CI, 28.71-49.44) in the control group for a rate ratio of 0.92 (95% CI, 0.62-1.36). The number needed to invite for screening to prevent 1 death from an AAA in 5 years was 4784 for men aged 64 to 83 years and 3290 for men aged 65 to 74 years. There were no meaningful differences in all-cause, cardiovascular, and other mortality risks.Use of the electoral roll to identify and invite men aged 64 to 83 years for screening for AAAs had no significant effect on the overall mortality from AAAs.isrctn.org Identifier: ISRCTN16171472.
GASTROPLASTIA ENDOSCÓPICA VS. GASTROPLASTIA QUIRÚRGICA VS. GASTRECTOMÍA VERTICAL. ESTUDIO COMPARATIVO DE SEGURIDAD Y EFICACIA EN OBESIDAD NO-MÓRBIDA
Authors: E Espinet Coll, J Nebreda Durán, G López-Nava Breviere, A García Ruiz De Gordejuela, M Galvao Neto, J Pujol Gebelli
Journal: Endoscopy (2016)

Durante los últimos años están apareciendo diferentes técnicas bariátricas restrictivas, tanto endoscópicas como quirúrgicas. Su aplicabilidad en obesidad no-mórbida no está bien establecida, por lo que se requiere de estudios comparativos.
TCT-825 Simplicity Denervation System for Pulmonary Artery Denervation in Patients with Chronic Thrombembolic Pulmonary Hypertension (first-in-man study)
Authors: Boris Rudenko, Artem Shanoian, Sergey Boytsov, Oksana Drapkina, Svetlana Beregovskaya, Anna Akhadova, Daria Feshchenko, Vsevolod Vlasov, Firdavs Shukurov, Alexandr Koltunov, Sergey Dzemeshkevich, Yulia Frolova
Journal: Journal of the American College of Cardiology (2016)
Quality of life in patients with advanced colorectal cancer treated with cetuximab: Results of the NCIC CTG and AGITG CO.17 trial
Authors: H. Au, C. Karapetis, D. Jonker, C. O’Callaghan, H. Kennecke, J. Shapiro, D. Tu, R. Wierzbicki, J. Zalcberg, M. Moore
Journal: Journal of Clinical Oncology (2007)

4002 Background: Cetuximab prolongs survival in pretreated advanced colorectal cancer (CRC) patients (pts). For these pts, the effect of palliative treatment on quality of life (QOL) is also an important outcome. Methods: CO.17 was a randomized controlled trial (n=572) of cetuximab combined with best supportive care (BSC) vs BSC alone in pts with pretreated epidermal growth factor receptor-positive advanced CRC. Primary endpoint was survival. QOL was a secondary endpoint using the EORTC QLQ-C30 at baseline, 4, 8, 16, and 24 weeks (wks). Primary endpoint for QOL compared physical function (PF) and global health status (Global) mean changes from baseline to 8 and 16 wks using Wilcoxon test. Negative change scores denote worsening QOL. The proportion of pts in either arm with at least a 10 unit deterioration at 8 and 16 wks from baseline was compared using Fischer’s exact test. Kaplan-Meier estimates and logrank tests on median time to definitive QOL deterioration, defined as at least a 10 unit deterioration in PF or Global, were evaluated. Exploratory analyses of all other scale and symptom change scores at 8 and 16 wks were also performed. Results: Compliance rates for QOL questionnaires was high at baseline, 94% each arm, but did drop off over time: 73% vs 60% at week 8 and 60% vs 39% at week 16 for cetuximab vs BSC, respectively. PF change scores at 8 wks were -3.9 for cetuximab vs -8.6 for BSC (p=.046); at 16 wks -5.9 vs -12.5 (p=.027). Global change scores were -0.5 vs -7.1 (p=.008) and -3.6 vs -15.2 (p=.008) at 8 and 16 wks respectively. The proportion of pts with deteriorating PF was 25% for cetuximab vs 35% for BSC at 8 wks (p=.051) and 30 vs 43% at 16 wks (p=.069). Deteriorating Global was seen in 23 vs 38% at 8 wks (p=.004) and 31 vs 49% at 16 wks (p=.0011). Time to PF deterioration was 5.4 months [95% CI 3.8–5.7] for cetuximab vs 3.7 months [2.0–3.9] for BSC (p=.022). Time to Global deterioration was 5.4 [3.9–5.7] vs 3.7 months [2.1–3.9] (p=.062). Exploratory analyses of all other scale and symptom change scores at 8 and 16 wks showed all differences of p&lt;.05 also favored cetuximab. Conclusions: Cetuximab provides palliation in pretreated pts with advanced CRC, delaying deterioration in QOL as well as improving survival. [Table: see text]
FACTORES PREDICTORES DE DIFICULTAD TÉCNICA EN DSE. DATOS PRELIMINARES DE UN ESTUDIO MULTICÉNTRICO
Authors: JC Marín-Gabriel, F Ramos-Zabala, LF Mugica-Aguinaga, J Díaz-Tasende, J De La Peña-García, E Albéniz-Urbizu, A Sánchez-Yagüe, O Nogales-Rincón, C Dolz-Abadía, A Álvarez
Journal: Endoscopy (2016)

Introducción: Definir situaciones de mayor dificultad técnica durante una disección submucosa (DSE) puede permitir optimizar la curva de aprendizaje evitando extirpar lesiones complejas al inicio.
Does Renal Repair Recapitulate Kidney Development?
Authors: Melissa Helen Little, Pamela Kairath
Journal: Journal of the American Society of Nephrology (2016)

Over a decade ago, it was proposed that the regulation of tubular repair in the kidney might involve the recapitulation of developmental pathways. Although the kidney cannot generate new nephrons after birth, suggesting a low level of regenerative competence, the tubular epithelial cells of the nephrons can proliferate to repair the damage after AKI. However, the debate continues over whether this repair involves a persistent progenitor population or any mature epithelial cell remaining after injury. Recent reports have highlighted the expression of Sox9, a transcription factor critical for normal kidney development, during postnatal epithelial repair in the kidney. Indeed, the proliferative response of the epithelium involves expression of several pathways previously described as being involved in kidney development. In some instances, these pathways are also apparently involved in the maladaptive responses observed after repeated injury. Whether development and repair in the kidney are the same processes or we are misinterpreting the similar expression of genes under different circumstances remains unknown. Here, we review the evidence for this link, concluding that such parallels in expression may more correctly represent the use of the same pathways in a distinct context, likely triggered by similar stressors.
Observational study designs
Authors: P. Sedgwick
Journal: BMJ (2012)

Researchers investigated whether pioglitazone was associated with an increased risk of bladder cancer in people with type 2 diabetes.1 Use of pioglitazone, an oral antidiabetic agent in the thiazolidinedione class, is controversial.2 The researchers used the general practice research database to extract data from individual patients’ primary care records between 1988 and 2009. A cohort of 115 727 patients with type 2 diabetes was established, with patients entering the cohort if they had been newly treated with oral hypoglycaemic agents. Patients were considered to have been exposed to pioglitazone if they had ever taken it, and measures of duration of use and cumulative dosage were recorded.

In the cohort 376 cases of bladder cancer were diagnosed. Patients were considered to be a case if their cancer was diagnosed at least one year after entry to the cohort, to account for latency. Each case was matched to as many as 20 controls on year of birth, year of cohort entry, sex, and duration of follow-up. A total of 6699 controls were identified. The researchers reported that the use of pioglitazone was associated with an increased risk of bladder cancer among people with type 2 diabetes. …
A phase I/II trial of radioimmunotherapy with <sup>131</sup>Iodine labelled A5B7 anti-CEA antibody (<sup>131</sup>I-A5B7) in combination with Combretastatin-A4-Phosphate (CA4P) in advanced gastrointestinal carcinomas
Authors: A. M. Gaya, J. Violet, G. Dancey, A. Green, M. Stratford, S. Sharma, K. Owen, A. Padhani, G. J. Rustin, R. H. Begent, T. Meyer
Journal: Journal of Clinical Oncology (2008)

14517 Background: In pre-clinical models the combination of radioimmunotherapy (RIT) with 131I-A5B7 and the vascular disruptive agent (VDA) CA4P was more effective than either agent alone, curing mice with CEA-positive colon carcinoma xenografts. Previous single agent phase I trials have defined the MTD for 131I-A5B7 at 2400MBq/m2 and CA4P between 60- 68mg/m2. We performed a Phase I/II trial to determine the DLT, MTD and efficacy of this combination in patients with advanced gastrointestinal cancer. Methods: Patients had advanced gastrointestinal adenocarcinoma, CEA 10–1000μg/L, disease measurable by RECIST, QTc ≤450 ms, no cardiac arrhythmia/ischaemia and adequate haematology/biochemistry. Disease had to be suitable for evaluation by dynamic MRI (DCE-MRI). All patients received a test dose of CA4P up to 2 weeks prior to Day 1, to document blood flow response. The starting dose was 1800MBq/m2 of 131I-A5B7 given on day 1 and 45mg/m2 CA4P given 48 and 72 hours post A5B7, and then weekly for up to seven weeks. Results: Twelve patients were treated; eleven colorectal and one pancreatic adenocarcinoma, mean age 63 (32–77), WHO PS 0(6) and 1(6). 2/6 patients at the first dose level had DLTs (grade 4 neutropenia) attributed to 131I-A5B7. The dose was reduced to 1600MBq/m2 and CA4P escalated to 54mg/m2. Again, 2/6 patients had DLTs attributable to 131I-A5B7 (grade 4 neutropaenia), and one patient had grade 3 ataxia (non-DLT). Of ten evaluable patients 1 had SD and 9 had PD, confirmed by FDG-PET in four. CA4P and A5B7 pharmacokinetics were similar to previous studies. SPECT confirmed tumour antibody uptake in all 5 patients studied. DCE-MRI confirmed falls in the kinetic parameters (Ktrans/IAUGC60) in 9/12 patients, statistically significant in 3/12 (p<0.05), 4 hours after the test dose of CA4P. Conclusions: This is the first clinical trial reporting on the combination of RIT and a VDA; each therapy component was shown to function but with dose-limiting myelosuppression from the combination at 66% of the single agent antibody MTD. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Cancer Research UK
Precipitating factors and 90‐day outcome of acute heart failure: a report from the intercontinental <scp>GREAT</scp> registry
Authors: Mattia Arrigo, Etienne Gayat, Jiri Parenica, Shiro Ishihara, Jian Zhang, Dong‐Ju Choi, Jin Joo Park, Khalid F. Alhabib, Naoki Sato, Oscar Miro, Aldo P. Maggioni, Yuhui Zhang, Jindrich Spinar, Alain Cohen‐Solal, Theodore J. Iwashyna, Alexandre Mebazaa
Journal: European Journal of Heart Failure (2016)
TCT-813 Alcohol Septal Ablation in patients with Left Ventricular Outflow Tract Obstruction after Transcatheter Mitral Valve Replacement for Mitral Annular Calcification (TMVR in MAC)
Authors: Pradeep Yadav, dee dee wang, Marvin Eng, Adam Greenbaum, William O'Neill
Journal: Journal of the American College of Cardiology (2016)
Response by Halperin and Savino to Letter Regarding Article, “Should Patients with Atrial Fibrillation and 1 Stroke Risk Factor (CHA <sub>2</sub> DS <sub>2</sub> -VASc Score 1 in Men, 2 in Women) Be Anticoagulated? The CHA <sub>2</sub> DS <sub>2</sub> -VASc 1 Conundrum: Decision Making at the Lower End of the Risk Spectrum”
Authors: Jonathan L. Halperin, John A. Savino
Journal: Circulation (2016)
Disease progression and overall survival in sardinian patients with colorectal cancer according to the kras mutational status
Authors: G. Palomba, A. Cossu, P. Paliogiannis, A. Pazzola, G. Baldino, M. Scartozzi, M.T. Ionta, S. Ortu, F. Capelli, A. Lanzillo, T. Sedda, G. Sanna, M. Barca, L. Virdis, M. Colombino, M. Casula, A. Manca, F. Tanda, M. Budroni, G. Palmieri
Journal: Annals of Oncology (2015)
Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR)
Authors: J. Sehouli, R. Chekerov, A. Reinthaller, R. Richter, A. Gonzalez-Martin, P. Harter, H. Woopen, E. Petru, L.C. Hanker, E. Keil, P. Wimberger, P. Klare, C. Kurzeder, F. Hilpert, A.K. Belau, A. Zeimet, I. Bover-Barcelo, U. Canzler, S. Mahner, W. Meier
Journal: Annals of Oncology (2016)
pMHC affinity controls duration of CD8+ T cell–DC interactions and imprints timing of effector differentiation versus expansion
Authors: Aleksandra J. Ozga, Federica Moalli, Jun Abe, Jim Swoger, James Sharpe, Dietmar Zehn, Mario Kreutzfeldt, Doron Merkler, Jorge Ripoll, Jens V. Stein
Journal: The Journal of Experimental Medicine (2016)

During adaptive immune responses, CD8+ T cells with low TCR affinities are released early into the circulation before high-affinity clones become dominant at later time points. How functional avidity maturation is orchestrated in lymphoid tissue and how low-affinity cells contribute to host protection remains unclear. In this study, we used intravital imaging of reactive lymph nodes (LNs) to show that T cells rapidly attached to dendritic cells irrespective of TCR affinity, whereas one day later, the duration of these stable interactions ceased progressively with lowering peptide major histocompatibility complex (pMHC) affinity. This correlated inversely BATF (basic leucine zipper transcription factor, ATF-like) and IRF4 (interferon-regulated factor 4) induction and timing of effector differentiation, as low affinity–primed T cells acquired cytotoxic activity earlier than high affinity–primed ones. After activation, low-affinity effector CD8+ T cells accumulated at efferent lymphatic vessels for egress, whereas high affinity–stimulated CD8+ T cells moved to interfollicular regions in a CXCR3-dependent manner for sustained pMHC stimulation and prolonged expansion. The early release of low-affinity effector T cells led to rapid target cell elimination outside reactive LNs. Our data provide a model for affinity-dependent spatiotemporal orchestration of CD8+ T cell activation inside LNs leading to functional avidity maturation and uncover a role for low-affinity effector T cells during early microbial containment.
The Addition of Rituximab to High Dose Sequential Chemotherapy (HDS) Programs with Autologous Transplantation Significantly Improves the Outcome of Patients with Refractory or Relapsed B-Cell Non Hogkin’s Lymphoma.
Authors: Sergio Cortelazzo, Andrea Rossi, Emanuela Carlotti, Piera Viero, Alessandro Rambaldi, Tiziano Barbui
Journal: Blood (2005)
TCT-157 Pretreatment with heparins and glycoprotein IIb/IIIa receptor inhibitors is associated with improved patency of infarct related-artery in STEMI – A report from SCAAR
Authors: Oscar Angeras, Christian Dworeck, Inger Haraldsson, Jacob Odenstedt, Dan Ioanes, Petur Petursson, Sebastian Volz, Per Albertsson, Jonas Persson, Sasha Koul, Björn Redfors, David Erlinge, Truls Råmunddal, Elmir Omerovic
Journal: Journal of the American College of Cardiology (2016)
Activity of Rapamycin in Patients with Relapsed, Refractory or Poor-Risk Acute Myeloid Leukemia.
Authors: Christian Recher, Odile Beyne-Rauzy, Cecile Demur, Françoise Huguet, Guy Laurent, Gaëtan Chicane, Cedric Dos Santos, Veronique Mansat-Demas, Bernard Payrastre
Journal: Blood (2004)
Prognostic Survival Associated With Left-Sided vs Right-Sided Colon Cancer
Authors: Fausto Petrelli, Gianluca Tomasello, Karen Borgonovo, Michele Ghidini, Luca Turati, Pierpaolo Dallera, Rodolfo Passalacqua, Giovanni Sgroi, Sandro Barni
Journal: JAMA Oncology (2016)

Primary tumor location is emerging as an important prognostic factor owing to distinct biological features. However, the side of origin of colon cancer (CC) still does not represent a prognostic parameter when deciding for adjuvant or palliative chemotherapy.To determine the prognostic role of left vs right-sidedness of primary tumor location in patients with CC.We searched PubMed, EMBASE, The Cochrane Library, Web of Science, LILACS, CINAHL, and SCOPUS for prospective or retrospective studies reporting data on overall survival for left-sided colon cancer (LCC) compared with right-sided colon cancer (RCC).Studies were selected if: (1) side of CC was reported among variables entered into survival analysis, (2) survival information was available (overall survival [OS] was reported in the article as hazard ratio (HR) according to multivariate analysis, (3) articles were published in the English language.Data were pooled using HRs for OS of LCC vs RCC according to fixed or random-effects models. Subgroup analysis and multivariate random-effects model meta-regression was also implemented adjusting for stage distribution, sample size, race, year of publication, type and quality of studies, and adjuvant chemotherapy.HRs for OS (the primary outcome measure) were pooled to provide an aggregate value. In this analysis, all HRs with 95% CIs were pooled to obtain prognostic information on the location of the primary tumor (left vs right location site of CC) independent of other common clinicopathological covariates.An analysis was made from the 66 studies conducted. It included 1 437 846 patients with a median follow-up of 65 months. Left sided primary tumor location was associated with a significantly reduced risk of death (HR, 0.82; 95% CI, 0.79-0.84; P < .001) and this was independent of stage, race, adjuvant chemotherapy, year of study, number of participants, and quality of included studies.Based on these results, CC side should be acknowledged as a criterion for establishing prognosis in all stages of disease. It should be considered when deciding treatment intensity in metastatic settings, and should represent a stratification factor for future adjuvant studies.
TCT-742 Transcatheter aortic valve implantation in patients aged ≤75 years versus &gt;75 years: a matched comparison
Authors: Marco Spaziano, Takahide Arai, Bernard Chevalier, Thomas Hovasse, Philippe Garot, None mauro romano, Hakim Benamer, Thierry Unterseeh, Erik Bouvier, Kentaro Hayashida, None yusuke watanabe, Bertrand Cormier, Marie-Claude Morice, Thierry Lefevre
Journal: Journal of the American College of Cardiology (2016)
TCT-54 LEADERS FREE OAC : Biolimus A9 coated versus bare metal stents in patients requiring oral anticoagulation. A pre-specified subgroup analysis of the LEADERS FREE trial
Authors: Didier Carrié, Ian Brian Alexander Menown, Keith Oldroyd, None samuel copt, Suneel Talwar, Luc Maillard, Marie-Claude Morice, Soo Teik Lim, Irene Lang, Philip Urban
Journal: Journal of the American College of Cardiology (2016)
Addition of Omega-3 α-Linolenic Acid to Platelet Apheresis Units Preserves Platelet Activatability Over Time and Reduces Baseline Activation Under Routine Storage Conditions: A Pilot Study
Authors: Simona Stivala, Sara C Meyer, Martin Reiner, Thomas F. Luscher, Andreas S. Buser, Juerg H. Beer
Journal: Blood (2012)
The Clinical Features and Prognosis of Early T-Cell Precursor Subtype of Lymphoblastic Lymphoma in the Japanese Pediatric Leukemia/Lymphoma Study Group ALB-NHL03 Study
Authors: Reiji Fukano, Shosuke Sunami, Masahiro Sekimizu, Tetsuya Takimoto, Tetsuya Mori, Tetsuo Mitsui, Takeshi Mori, Akiko Moriya Saito, Tomoyuki Watanabe, Koichi Ohshima, Junichiro Fujimoto, Atsuko Nakazawa, Nobutaka Kiyokawa, Ryoji Kobayashi, Keizo Horibe, Masahito Tsurusawa
Journal: Blood (2014)